Volume 10, Issue 3 (7-2012)                   IJRM 2012, 10(3): 229-236 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sohrabvand F, Sheikhhassani S, Bagheri M, Haghollahi F, Shabihkhani M, Shariat M et al . Comparison of highly purified urinary versus recombinant FSH: Effect on ART outcomes in polycystic ovary syndrome. IJRM 2012; 10 (3) :229-236
URL: http://ijrm.ir/article-1-280-en.html
Comparison of highly purified urinary versus recombinant FSH: Effect on ART outcomes in polycystic ovary syndrome
Farnaz Sohrabvand * 1, Shahrzad Sheikhhassani2 , Maryam Bagheri3 , Fedyeh Haghollahi3 , Maryam Shabihkhani3 , Mamak Shariat4 , Manijeh Nasr Esfahani3
1- Department of Obstetrics- Gynecology and Infertility, Vali-e-Asr Hospital, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran , fsohrabvand@yahoo.com
2- Department of Obstetrics- Gynecology and Infertility, Vali-e-Asr Hospital, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
3- Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran
4- Maternal- Fetal and Neonatal Research Center, Tehran University of Medical Sciences, Tehran, Iran
Abstract:   (3133 Views)
Background: Polycystic ovary syndrome (PCOS) is a common cause of ovulatory disorders and infertility with high LH to FSH ratio. In order to prevent further increase of LH and follicle atresia, different regimens for ovulation induction have been recommended using FSH alone.  
Objective: This study was performed in PCOS patients to compare ART outcomes in cycles induced by FSH alone, using either recombinant or urinary products.  
Materials and Methods: In a randomized trial, from 623 patients who underwent down regulation with GnRH analogue in a long protocol, 160 PCOS patients were randomly divided into two groups of 80. Group A received 150 IU/d recombinant FSH (Gonal-F) and group B 150 IU/d urinary FSH (Fostimon).
Results: 33 cases (41.2%) in group A and 36 (45%) in group B achieved clinical pregnancy, which was not significantly different (p=0.67). Total number of oocytes retrieved (13.03±5.56 vs. 14.17±4.89, p=0.17), quality and number of embryos (7.42±3.35 vs. 7.63±3.28, p=0.68) and OHSS rate were similar in group A compared to group B. Endometrial thickness which was 9.66±1.67 mm in group A and 10.36±1.35 mm in group B, showed a significant difference (p=0.004).
Conclusion: It seems that in PCOS patients, both pure FSH products used for controlled ovarian hyperstimulation have similar effects on ART outcome and can be used according to availability and patient acceptance without significant difference.
Keywords: ART outcome, PCOS, Highly purified urinary FSH, Recombinant FSH, Clinical pregnancy rate
Full-Text [PDF 466 kb]   (556 Downloads) |   |   Full-Text (HTML)  (268 Views)  
Type of Study: Original Article |
References
1. Forti G, Krausz C. Clinical review 100: Evaluation and treatment of the infertile couple. J Clin Endicrinol Metab 1998; 83: 4177-4188.
2. Taymar Ml. Regulation of follicle growth: some clinical implications in reproductive endocrinology. Fertil Steril 1996; 65: 235-247. [DOI:10.1016/S0015-0282(16)58077-7]
3. Fauser BC, Van heudsen AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocrine Rev 1997; 18: 71-106.
4. Lenton E, Soltan A, Hewitt J, Thomson A, Davies W, Ashraf N, et al. Induction of ovulation in women undergoing assisted reproductive techniques: recombinant human FSH (follitropin alpha) versus highly purified urinary FSH (urofollitropin HP). Hum Reprod 2000; 15:1021-1027. [DOI:10.1093/humrep/15.5.1021]
5. White DM, Polson DW, Kiddy D, Sagle P, Watson H, Gilling-Smith C, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996; 81:3821-3824.
6. Taymor ML. The regulation of follicle growth: some clinical implications in reproductive endocrinology. Fertil Steril 1996; 65: 235-247. [DOI:10.1016/S0015-0282(16)58077-7]
7. Simoni M, Jockenhövel F, Nieschlag E. Biological and immunological properties of the international standard for FSH 83/575: isoelectrofocusing profile and comparison with other FSH preparations. Acta Endocrinol (Copenh) 1993; 128:281-288. [DOI:10.1530/acta.0.1280281]
8. Hummel WP, Kettel LM. Assisted reproductive technology: the state of the ART. Ann Med 1997; 29: 207-214. [DOI:10.3109/07853899708999338]
9. Balasch J, Fábregues F, Arroyo V. Peripheral arterial vasodilation hypothesis: a new insight into the pathogenesis of ovarian hyper-stimulation syndrome. Hum Reprod 1998; 13: 2718-2730. [DOI:10.1093/humrep/13.10.2718]
10. Hillier SG. Ovarian manipulation with pure gonadotropins. J Endocrinol 1990; 127: 1-4. [DOI:10.1677/joe.0.1270001]
11. Loumaye E, Martineau I, Piazzi A, O'Dea L, Ince S, Howles C, et al. Clinical assessment of human gonadotrophins produced by recombinant technology. Hum Reprod 1996: 11 (suppl.): 95-107. [DOI:10.1093/humrep/11.suppl_5.95]
12. Aboulghar MA, Mansour RT, Serour GI, Amin YM, Sattar MA, elAttar E. Recombinant follicle-stimulating hormone in the treatment of patients with history of severe ovarian hyperstimulation syndrome. Fertil Steril 1996; 66:757-760. [DOI:10.1016/S0015-0282(16)58631-2]
13. Van Wely M, Bayram N, van der Veen F Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review. Hum Reprod 2003; 18: 1143-1149. [DOI:10.1093/humrep/deg229]
14. Azziz R. The Rotteram Criteria are premature. J Clin Endocrinol Metab 2006; 91: 781-785. [DOI:10.1210/jc.2005-2153]
15. Veeck L. Oocyte assessment and biological performance. Ann N Y Acad Sci 1988; 541: 259-274. [DOI:10.1111/j.1749-6632.1988.tb22263.x]
16. Veeck L. An atlas of human gametes and conception. London, Parthenon; 1999. [DOI:10.1201/b14639]
17. Pakarainen F, Zhang, FP, Nurmi L, Poutanen M, Huhtaniemi I. Knockout of luteinizing hormone receptor abolishes the effects of follicle-stimulating hormone on preovulatory maturation and ovulation of mouse graafian follicles. Mol Endocrinol 2005; 19: 2591-2602. [DOI:10.1210/me.2005-0075]
18. Strehler E, Abt M, El-Danasouri I, De Santo M, Sterzik K. Impact of recombinant follicle-stimulating hormone and human menopausal gonadotropins on in vitro fertilization outcome. Fertil Steril 2001; 75: 332-326. [DOI:10.1016/S0015-0282(00)01696-4]
19. Daya, S, Gunby J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles (Cochrane Review). The Cochrane Library, Issue 2. Oxford, Update Software; 2002.
20. Palagiano A, Nesti E, Pace L. FSH: urinary and recombinant. Eur J Obstet Gynecol Reprod Biol 2004; 115 (Suppl.): 30-33. [DOI:10.1016/j.ejogrb.2004.01.023]
21. Al-Inany H, Aboulghar M, Mansour R, SerourG.Meta-analysis of recombinant versus urinary-derived FSH: an update. Hum Reprod 2003; 18: 305-313. [DOI:10.1093/humrep/deg088]
22. Abate A, Nazzaro A, Salerno A, Marzano F, Pavone Cossut MR, Perino M. Efficacy of recombinant versus human derived follicle stimulating hormone on the oocyte and embryo quality in IVF-ICSI cycles: Randomised, controlled, multi-centre trial. Gynecol Endocrinol 2009; 25: 479-484. [DOI:10.1080/09513590902770156]
23. Selman HA, De Santo M, Sterzik K, Coccia E, El-Danasouri I. Effect of highly purified urinary follicle-stimulating hormone on oocyte and embryo quality. Fertil Steril 2002; 78: 1061-1067. [DOI:10.1016/S0015-0282(02)04202-4]
24. Manassiev NS, Tenekedjier KI, Collins J. Does the use of recombinant follicle-stimulating hormone instead of urinary follicle-stimulating hormone lead to higher pregnancy rates in in-vitro fertilisation-embryo transfer cycles? Assist Reprod 1999; 9: 7-12.
25. Balen A, Platteau P, Andersen AN, Devroey P, Helmgaard L, Arce JC. Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women with WHO Group II anovulatory infertility: a randomized controlled non-inferiority trial. Hum Reprod 2007; 22: 1816-1823. [DOI:10.1093/humrep/dem075]
26. Bayram N, van Wely M, van Der Veen F. Recombinant FSH versus urinary gonadotrophins or recombinant FSH for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2001: CD002121. [DOI:10.1002/14651858.CD002121]
27. Corbacioğlu A, Baysal B. Effects of endometrial thickness and echogenic pattern on assisted reproductive treatment outcome. Clin Exp Obstet Gynecol 2009; 36: 145-147.
28. le Cotonnec JY, Porchet HC, Beltrami V, Khan A, Toon S, Rowland M. Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil Steril 1994; 61: 669-678.
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb